Basic Information
LncRNA/CircRNA Name | circFARSA |
Synonyms | |
Region | |
Ensemble | |
Refseq |
Classification Information
Regulatory Mechanism | Biological Function | Clinical Application | |||
---|---|---|---|---|---|
TF | Immune | Survival | |||
Enhancer | Apoptosis | Drug | |||
Variant | Cell Growth | Circulating | |||
MiRNA | EMT | Metastasis | |||
Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
Cancer Name | non small cell lung cancer |
ICD-0-3 | C34 |
Methods | qPCR, RNA-seq, other |
Sample | lung cancer tissues cell line (A549), plasma |
Expression Pattern | up-regulated |
Function Description | A circRNA derived from exon 5-7 of the FARSA gene, termed circFARSA, was observed to increase in cancerous tissues (P = 0.016), and was more abundant in patients' plasma than controls (P < 0.001). Overexpression of circFARSA in A549 cell line significantly promoted cell migration and invasion. In silico analysis suggested that circFARSA might sponge miR-330-5p and miR-326, thereby relieving their inhibitory effects on oncogene fatty acid synthase. Summarily, this study revealed circRNA profile of NSCLC for the first time and provided the evidence of plasma circFARSA as a potential noninvasive biomarker for this malignancy. |
Pubmed ID | 29722168 |
Year | 2018 |
Title | A Novel Plasma Circular RNA circFARSA Is a Potential Biomarker for Non-Small Cell Lung Cancer |
External Links
Links for circFARSA | GenBank HGNC NONCODE |
Links for non small cell lung cancer | OMIM COSMIC |